Information Provided By:
Fly News Breaks for June 8, 2015
BAYRY
Jun 8, 2015 | 07:54 EDT
Bernstein says that data on Bayer's Finerenone drug has been "decent but not revolutionary," suggesting that it would be safer but have similar efficacy to its existing MRA competitors.Still, the firm thinks the drug has a 75% chance of being approved as a treatment for diabetes nephropathy and CHF, and could become "a blockbuster drug" with "even moderate penetratio."The firm warns that the drug does face some competitive challenges, but estimates that it can generate $1.3B-$2B in peak sales and keeps an Outperform rating on the stock.
News For BAYRY From the Last 2 Days
There are no results for your query BAYRY